GlaxoSmithKline plc - Asset Resilience Ratio

Latest as of September 2025: 0.02%

GlaxoSmithKline plc (GSKN) has an Asset Resilience Ratio of 0.02% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check GSKN strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

MX$10.00 Million
≈ $575.50K USD Cash + Short-term Investments

Total Assets

MX$61.34 Billion
≈ $3.53 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2013–2024)

This chart shows how GlaxoSmithKline plc's Asset Resilience Ratio has changed over time. See GlaxoSmithKline plc net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down GlaxoSmithKline plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GSKN stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents MX$0.00 0%
Short-term Investments MX$10.00 Million 0.02%
Total Liquid Assets MX$10.00 Million 0.02%

Asset Resilience Insights

  • Limited Liquidity: GlaxoSmithKline plc maintains only 0.02% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

GlaxoSmithKline plc Industry Peers by Asset Resilience Ratio

Compare GlaxoSmithKline plc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
AbbVie Inc
NYSE:ABBV
Drug Manufacturers - General 0.02%
Novartis AG
SW:NOVN
Drug Manufacturers - General 0.08%
Pfizer Inc
SA:PFIZ34
Drug Manufacturers - General 5.48%
Pfizer Inc
NYSE:PFE
Drug Manufacturers - General 5.48%
Firebrick Pharma Ltd
AU:FRE
Drug Manufacturers - General 0.29%
Eli Lilly and Company
SA:LILY34
Drug Manufacturers - General 8.63%
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
Drug Manufacturers - General 7.83%
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
Drug Manufacturers - General 17.40%

Annual Asset Resilience Ratio for GlaxoSmithKline plc (2013–2024)

The table below shows the annual Asset Resilience Ratio data for GlaxoSmithKline plc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.04% MX$21.00 Million
≈ $1.21 Million
MX$59.46 Billion
≈ $3.42 Billion
-3.77pp
2023-12-31 3.81% MX$2.25 Billion
≈ $129.26 Million
MX$59.01 Billion
≈ $3.40 Billion
-3.10pp
2022-12-31 6.91% MX$4.15 Billion
≈ $239.06 Million
MX$60.15 Billion
≈ $3.46 Billion
+6.83pp
2021-12-31 0.08% MX$61.00 Million
≈ $3.51 Million
MX$79.10 Billion
≈ $4.55 Billion
-0.02pp
2020-12-31 0.10% MX$78.00 Million
≈ $4.49 Million
MX$80.43 Billion
≈ $4.63 Billion
0.00pp
2019-12-31 0.10% MX$79.00 Million
≈ $4.55 Million
MX$79.69 Billion
≈ $4.59 Billion
-0.05pp
2018-12-31 0.14% MX$84.00 Million
≈ $4.83 Million
MX$58.07 Billion
≈ $3.34 Billion
+0.01pp
2017-12-31 0.14% MX$78.00 Million
≈ $4.49 Million
MX$56.38 Billion
≈ $3.24 Billion
-0.01pp
2016-12-31 0.15% MX$89.00 Million
≈ $5.12 Million
MX$59.08 Billion
≈ $3.40 Billion
+0.01pp
2015-12-31 0.14% MX$75.00 Million
≈ $4.32 Million
MX$53.45 Billion
≈ $3.08 Billion
-0.03pp
2014-12-31 0.17% MX$69.00 Million
≈ $3.97 Million
MX$40.65 Billion
≈ $2.34 Billion
+0.01pp
2013-12-31 0.16% MX$66.00 Million
≈ $3.80 Million
MX$42.09 Billion
≈ $2.42 Billion
--
pp = percentage points

About GlaxoSmithKline plc

MX:GSKN Mexico Drug Manufacturers - General
Market Cap
$104.06 Billion
MX$1.81 Trillion MXN
Market Cap Rank
#238 Global
#9 in Mexico
Share Price
MX$901.11
Change (1 day)
-0.98%
52-Week Range
MX$710.00 - MX$1041.90
All Time High
MX$1096.34
About

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more